• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics (7th Edition) Product Image

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics (7th Edition)

  • ID: 2624228
  • December 2014
  • Region: Global
  • 310 Pages
  • CurrentPartnering

FEATURED COMPANIES

  • AcuFocus
  • Bioniche Life Sciences
  • Fumapharm
  • MediGene
  • PBS Capital Management
  • SV Life Science
  • MORE

The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.

Comprehensive directory of royalty financing deals since 2007
Royalty financing contract documents
Royalty financing agreement terms
Royalty financing agreement structure
Top royalty financing deals by value
Most active Royalty financing dealmakers

The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AcuFocus
  • Bioniche Life Sciences
  • Fumapharm
  • MediGene
  • PBS Capital Management
  • SV Life Science
  • MORE

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

2.1. Introduction
2.2. Difference between royalty and revenue financing deals
2.3. Trends in royalty financing deals since 2007
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. Recent royalty asset purchase deals
2.5.3. The role of big pharma in royalty buyback
2.5.4. The future of royalty asset purchase deals

Chapter 3 - Overview of royalty financing structure

3.1. Introduction
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Xoma - UCB - Orbimed Advisors - August 2010
3.3.2. Case study 2: Dyax - Paul Capital Healthcare - April 2010
3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals -Shionogi- March 2011
3.3.4. Case study 4: Royalty asset: TPG - CV Therapeutics - April 2008

Chapter 4 - Leading royalty financing deals

4.1. Introduction
4.2. Top royalty financing deals by value
4.3. Top revenue financing deals by value
4.4. Most active royalty financing dealmakers

Chapter 5 - Royalty financing contract documents 2007-2014

5.1. Introduction
5.2. Company A-Z

Chapter 6 - Royalty financing agreement directory 2007-2014

6.1. Introduction
6.2. Company A-Z
6.3. By therapy area

Appendix
Appendix 1 - Royalty financing references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example royalty financing contract document
Recent report titles
Order Form - Upgrades to subscription access products
Order Form - Reports

TABLE OF FIGURES

Figure 1: Definition of royalty assets
Figure 2: Trends in royalty financing deal announcements, 2007-2014
Figure 3: Trends in revenue financing or ‘synthetic royalty’ deal announcements, 2007-2014
Figure 4: Leading royalty asset investors
Figure 5: Leading royalty asset purchase agreements
Figure 6: Components of the royalty asset purchase deal structure
Figure 7: Top royalty financing deals by value since 2007
Figure 8: Top revenue financing deals by value since 2007
Figure 9: Most active royalty financing dealmakers 2007-2014
Figure 10: Online partnering resources
Figure 11: Deal type definitions
Figure 12: Royalty financing agreement for Qutenza - April 2010

Note: Product cover images may vary from those shown

Accuitive Medical Ventures
AcuFocus
Aisling Capital
Alexza Pharmaceuticals
Allon Therapeutics
Amgen
Aradigm
Artes Biotechnology
Astellas Pharma Europe
AxoGen
Bausch & Lomb
Bess Royalty
Biogen Idec
Bioniche Life Sciences
CPPIB Credit Investments
Capital Royalty
Children's Hospital of Philadelphia
Clarus Ventures
Corcept Therapeutics
Cowen Healthcare Royalty Partners
DRI Capital
Deerfield Management
Dendreon
DepoMed
Dyax
Elan
Forest Laboratories
Fumapharm
Furiex Pharma
Glaxo Group
GlaxoSmithKline
Hana Biosciences
Healthcare Royalty Partners
Human Genome Sciences
InSite Vision
Indevus Pharmaceuticals
Innexus
Isar Pharma
LifeCycle Pharma
Litmus
MediGene
Medtronic
MiddleBrook Pharmaceutical
NPS Pharmaceuticals
Nektar Therapeutics
NeurogesX
New York University
Northwestern University
Novo
Nuron Biotech
Ophthotech
Orbimed Advisors
PBS Capital Management
PDL BioPharma
Paul Capital Healthcare
Pharmakon Advisors
Phase III Development Company
Plethora Solutions
Pozen
Quest Diagnostics
Royalty Pharma
Royalty Securitization Trust
Rush University Medical Center
SV Life Science
SWK Funding
SkyePharma
Spepharm Holding
Stereotaxis
Suneva Medical
Supernus Pharmaceuticals
TearScience
The Carlyle Group
Theravance
Titan Pharmaceuticals
UCB
Unilife
Vernalis
Versant Ventures
Vertex Pharmaceuticals
Vivione Biosciences
Vivus
Zogenix
ZymoGenetics

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos